Pazopanib is a targeted therapy medication primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. As a tyrosine kinase inhibitor, pazopanib works by blocking the action of certain enzymes called tyrosine kinases, which are involved in the growth and spread of cancer cells. By inhibiting these enzymes, pazopanib helps slow down or stop the growth of cancer cells, thereby delaying the progression of the disease and improving patient outcomes. Additionally, pazopanib may also be prescribed for other types of cancers, such as advanced ovarian cancer and advanced non-small cell lung cancer, under the guidance of a healthcare professional.

One of the key features of pazopanib is its oral administration, making it a convenient treatment option for patients compared to traditional intravenous chemotherapy. This allows patients to take their medication at home without the need for frequent hospital visits, enhancing their quality of life and providing greater flexibility in managing their treatment schedule. Furthermore, pazopanib has demonstrated efficacy in clinical trials, showing significant improvements in progression-free survival and overall survival rates in patients with advanced renal cell carcinoma and soft tissue sarcoma. It is often used as a first-line or second-line treatment option, either alone or in combination with other cancer therapies, based on individual patient characteristics and treatment goals.